Emerald Advisers LLC Sells 1,339 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

Emerald Advisers LLC cut its holdings in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 0.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 732,660 shares of the medical device company’s stock after selling 1,339 shares during the quarter. Emerald Advisers LLC’s holdings in Orthofix Medical were worth $11,444,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of OFIX. nVerses Capital LLC bought a new stake in Orthofix Medical during the second quarter valued at about $27,000. Quest Partners LLC bought a new stake in shares of Orthofix Medical in the second quarter worth about $64,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Orthofix Medical by 25.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,435 shares of the medical device company’s stock worth $125,000 after purchasing an additional 1,919 shares during the last quarter. Arizona State Retirement System bought a new stake in shares of Orthofix Medical in the second quarter worth about $139,000. Finally, XTX Topco Ltd bought a new stake in shares of Orthofix Medical in the second quarter worth about $175,000. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Price Performance

Shares of OFIX stock traded up $0.77 during trading hours on Friday, hitting $16.96. The stock had a trading volume of 213,514 shares, compared to its average volume of 193,933. Orthofix Medical Inc. has a one year low of $9.57 and a one year high of $17.67. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.48 and a quick ratio of 1.13. The stock’s 50-day moving average price is $16.15 and its two-hundred day moving average price is $15.10. The stock has a market capitalization of $647.45 million, a price-to-earnings ratio of -5.32 and a beta of 1.05.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Tuesday, August 6th. The medical device company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.58). Orthofix Medical had a negative return on equity of 20.68% and a negative net margin of 15.61%. The firm had revenue of $198.62 million during the quarter, compared to the consensus estimate of $195.75 million. Equities analysts forecast that Orthofix Medical Inc. will post -2.13 EPS for the current year.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.